Thank you for your medical contributions! I take your experience and believe your pronouncements on the medical efficacy of Leronlimab. Unfortunately almost all of the investors like myself and investment houses do not have the medical background to appreciate those numbers on the respiratory distress. The pr person at Cydy needs to do a much better job of preparing NP for his interviews. Know the interests of your interlocutor and the interests of the audience. I also agree very much with the sense of the board that double blind studies are wrong in the face of so much death. I have complained to our Congresswoman, Bloomberg, Gates, the Democrats, and others. This is an ivory tower attitude that needs to change.
Market Data 
Markets 
AI
